HomeDiscoveryPipeline

Pipeline

Nerviano Medical Sciences' current portfolio includes anticancer compounds in clinical phase or in advanced stage of pre clinical development, in addition to research projects.
Several projects are conducted within strategic alliances.

ENCORAFENIB
B-RAF melanoma combo
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ENCORAFENIB
B-RAF CRC combo
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ENTRECTINIB
ROS NSCLC
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ENTRECTINIB
TRK solid tumors
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ONVANSERTIB
AML & solid tumor combo
PRECLINICAL PHASE I PHASE II PHASE III
63% PHASE II
MILCICLIB
HCC
PRECLINICAL PHASE I PHASE II PHASE III
63% PHASE II
-----
PRECLINICAL PHASE I PHASE II PHASE III
A602
(Danusertib)
PRECLINICAL PHASE I PHASE II PHASE III
50% PHASE I
M912 SA
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
M801 SA
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
M801 combo
PRECLINICAL PHASE I PHASE II PHASE III
20% PRECLINICAL
P707 SA
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
P707 combo
PRECLINICAL PHASE I PHASE II PHASE III
20% PRECLINICAL
P807
PRECLINICAL PHASE I PHASE II PHASE III
20% PRECLINICAL
Early Pipeline
PRECLINICAL PHASE I PHASE II PHASE III
13% PRECLINICAL